Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Adherence with urate-lowering therapies for the treatment of gout.

Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS.

Arthritis Res Ther. 2009;11(2):R46. doi: 10.1186/ar2659. Epub 2009 Mar 27.

2.

Adherence and persistence to urate-lowering therapies in the Irish setting.

McGowan B, Bennett K, Silke C, Whelan B.

Clin Rheumatol. 2016 Mar;35(3):715-21. doi: 10.1007/s10067-014-2823-8. Epub 2014 Nov 20.

PMID:
25409858
3.

Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.

Solomon DH, Avorn J, Levin R, Brookhart MA.

Ann Rheum Dis. 2008 May;67(5):609-13. Epub 2007 Aug 29.

PMID:
17728328
4.

Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.

Thiele RG, Schlesinger N.

Rheumatol Int. 2010 Feb;30(4):495-503. doi: 10.1007/s00296-009-1002-8. Epub 2009 Jun 20.

PMID:
19543895
5.

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.

PMID:
19485724
6.

Uricosuric medications for chronic gout.

Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C.

Cochrane Database Syst Rev. 2014 Nov 14;(11):CD010457. doi: 10.1002/14651858.CD010457.pub2.

PMID:
25392987
7.

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.

Mitri G, Wittbrodt ET, Turpin RS, Tidwell BA, Schulman KL.

J Manag Care Spec Pharm. 2016 Apr;22(4):326-36. doi: 10.18553/jmcp.2016.22.4.326.

8.

Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.

Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR.

J Rheumatol. 2015 Mar;42(3):504-12. doi: 10.3899/jrheum.140588. Epub 2014 Dec 15.

9.

Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.

Castrejon I, Toledano E, Rosario MP, Loza E, PĂ©rez-Ruiz F, Carmona L.

Rheumatol Int. 2015 Jul;35(7):1127-37. doi: 10.1007/s00296-014-3189-6. Epub 2014 Dec 18. Review. Erratum in: Rheumatol Int. 2015 Jul;35(7):1139.

PMID:
25519877
10.

The dynamics of chronic gout treatment: medication gaps and return to therapy.

Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS.

Am J Med. 2010 Jan;123(1):54-9. doi: 10.1016/j.amjmed.2009.05.026.

11.

Opportunities for improving medication use and monitoring in gout.

Singh JA, Hodges JS, Asch SM.

Ann Rheum Dis. 2009 Aug;68(8):1265-70. doi: 10.1136/ard.2008.092619. Epub 2008 Aug 13.

PMID:
18701554
12.

Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.

Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G.

Rheumatology (Oxford). 2013 Jun;52(6):1126-31. doi: 10.1093/rheumatology/kes431. Epub 2013 Feb 7.

PMID:
23392592
13.

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jan;68(1):51-6. doi: 10.1136/ard.2007.083071. Epub 2008 Feb 4.

PMID:
18250112
14.

Sex differences in gout epidemiology: evaluation and treatment.

Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG.

Ann Rheum Dis. 2006 Oct;65(10):1368-72. Epub 2006 Apr 27.

15.

Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Hill EM, Sky K, Sit M, Collamer A, Higgs J.

J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.

PMID:
25807090
16.

Allopurinol use in a New Zealand population: prevalence and adherence.

Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J, Keown S, Herbison P.

Rheumatol Int. 2014 Jul;34(7):963-70. doi: 10.1007/s00296-013-2935-5. Epub 2014 Jan 4.

PMID:
24390636
17.

Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW.

Mayo Clin Proc. 2006 Jul;81(7):925-34.

PMID:
16835972
18.

Allopurinol for chronic gout.

Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 14;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3. Review.

PMID:
25314636
19.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
20.

The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.

Yin R, Cao H, Fu T, Zhang Q, Zhang L, Li L, Gu Z.

Rheumatol Int. 2017 Jul;37(7):1187-1194. doi: 10.1007/s00296-017-3746-x. Epub 2017 May 27.

PMID:
28551724

Supplemental Content

Support Center